Nov 29 2018
Auris was featured on Compelo, a online news publication covering medical devices, about additional funding received to advance the Monarch Platform.
Auris secured $220 million in equity financing under the financing round led by Partner Fund Management. Wellington Management, D1 Capital Partners, Senator Investment Group, Mithril Capital, Lux Capital and Viking Global Investors also participated in the round. These additional funds will be used to advance the commercialization of the Monarch Platform and develop the next generation of interventional technology in robotics. Auris has raised over $700 million to date in funding, including this recent addition.
Auris has already received FDA approval to use the Monarch Platform for diagnostic and therapeutic bronchoscopy procedures. The platform allows physicians to navigate the flexible bronchoscope to the periphery of the lung using a controller interface. The platform provides the physician with continuous bronchoscope vision, computer guidance, and very precise control throughout the procedure. This technology allows physicians to more accurately diagnose and treat small and hard-to-reach nodules in the periphery of the lung. Lung cancer is one of the top causes of cancer deaths across the world, and early diagnosis can lead to a better prognosis for patients.
This additional funding will help further Auris's plans to advance medical intervention by incorporating robotic, micro-instrumentation, endoscope design, sensing, and data science into a single platform, optimizing both physician capabilities and patient outcomes.
The article includes a quote from Auris Health CEO Dr. Frederic Moll, who said of the additional funding: "We are pleased with our progress in launching the Monarch Platform, which was initiated earlier this year. This funding will enable us to expand our commercialization efforts for endobronchial applications, and will also support our mission to pioneer the next era of medical intervention across a broader spectrum of procedures."Read the Full Article on Compelo
Bronchoscopy Important Safety Statement:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Important Safety Statement:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.